Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV
- PMID: 20934437
- DOI: 10.1016/j.lfs.2010.10.002
Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV
Abstract
Prior to the era of highly active anti-retroviral therapy (HAART), cohort studies provided equivocal evidence to support the hypothesis that substance use predicts more rapid HIV disease progression. The present review examined the effects of substance use on HIV disease progression in cohort studies with follow-up that continued into the HAART era. Of the 20 studies included in this review, 16 observed that substance use predicted at least one indicator of HIV disease progression. Ten of the 11 studies that followed participants exclusively in the HAART era observed an effect of substance use on HIV disease progression. Findings across studies indicate that stimulant use promotes more rapid HIV disease progression and the effects of substance use on HIV disease progression can persist after controlling for self-reported HAART non-adherence. Future investigations that examine the bio-behavioral pathways whereby substance use promotes HIV disease progression should include: measures of HIV genotypic and phenotypic resistance, multi-method assessment of adherence, and assessment of co-morbid infections that are more prevalent among substance users. Although further mechanistic research is needed, findings from existing cohort studies have clear clinical implications. Implementing screening, brief intervention and referral to substance abuse treatment in HIV medical care could optimize health outcomes and decrease HIV transmission rates by boosting the effectiveness of "Test and Treat" approaches to HIV prevention.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART).Life Sci. 2011 May 23;88(21-22):909-16. doi: 10.1016/j.lfs.2011.03.022. Epub 2011 Apr 6. Life Sci. 2011. PMID: 21477599
-
Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.Antivir Ther. 2005;10(1):53-61. Antivir Ther. 2005. PMID: 15751763
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy: the role of drugs of abuse.Life Sci. 2011 May 23;88(21-22):922-5. doi: 10.1016/j.lfs.2011.03.006. Epub 2011 Mar 31. Life Sci. 2011. PMID: 21439978 Review.
-
Optimizing treatment outcomes in HIV-infected patients with substance abuse issues.Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S318-23. doi: 10.1086/522557. Clin Infect Dis. 2007. PMID: 18190306
Cited by
-
Engagement in HIV Medical Care and Technology Use among Stimulant-Using and Nonstimulant-Using Men who have Sex with Men.AIDS Res Treat. 2013;2013:121352. doi: 10.1155/2013/121352. Epub 2013 Jun 23. AIDS Res Treat. 2013. PMID: 23864944 Free PMC article.
-
Brief Report: Hazardous Cannabis Use and Monocyte Activation Among Methamphetamine Users With Treated HIV Infection.J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):361-364. doi: 10.1097/QAI.0000000000002046. J Acquir Immune Defic Syndr. 2019. PMID: 30958388 Free PMC article.
-
Getting to Zero: Targeting Psychiatric Comorbidities as Drivers of the HIV/AIDS Epidemic.Int J Behav Med. 2019 Feb;26(1):1-2. doi: 10.1007/s12529-019-09771-w. Int J Behav Med. 2019. PMID: 30725353 No abstract available.
-
Intervention to Increase HIV Testing Among Substance-Using Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial.JMIR Res Protoc. 2018 Apr 30;7(4):e114. doi: 10.2196/resprot.9414. JMIR Res Protoc. 2018. PMID: 29712625 Free PMC article.
-
Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy.J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):508-13. doi: 10.1097/QAI.0000000000000364. J Acquir Immune Defic Syndr. 2014. PMID: 25271387 Free PMC article.